Adicet Bio Files 8-K: Financial Statements & Exhibits

TL;DR

Adicet Bio filed an 8-K with financial statements and exhibits on 9/30/24.

AI Summary

On September 30, 2024, Adicet Bio, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update rather than a significant event. No specific financial figures or material business developments were detailed in the provided excerpt.

Why It Matters

This filing serves as a standard disclosure for Adicet Bio, Inc., providing updates on their financial statements and exhibits as required by the SEC.

Risk Assessment

Risk Level: low — The filing appears to be a routine disclosure of financial statements and exhibits, with no immediate indication of significant new risks or material events.

Key Players & Entities

• Adicet Bio, Inc. (company) — Registrant
• September 30, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of Incorporation
• Boston, Massachusetts (location) — Address of Principal Executive Offices

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share ACET The Nasdaq Global Ma

Filing Documents

• acet-20240930.htm (8-K) — 45KB
• acet-ex99_1.htm (EX-99.1) — 21KB
• img94724212_0.jpg (GRAPHIC) — 2KB
• 0000950170-24-110166.txt ( ) — 186KB
• acet-20240930.xsd (EX-101.SCH) — 24KB
• acet-20240930_htm.xml (XML) — 5KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On September 30, 2024, Adicet Bio, Inc. (Adicet or the Company) issued a press release titled "Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases," a copy of which is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Other Events

Item 8.01 Other Events. On September 30, 2024, the Company announced the activation of clinical sites for its Phase 1 trial of ADI-001 in autoimmune diseases including lupus nephritis (LN), systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and anti-neutrophil cytoplasmic autoantibody (ANCA) associated vasculitis (AAV). The sites are currently open to enroll patients with LN and the Company plans to initiate enrollment of patients with SLE, SSc and AAV in the fourth quarter of this year. Additionally, the Company plans to report on preliminary clinical data from this trial of ADI-001 in LN as well as SLE, SSc and AAV in the first half of 2025.

Forward-Looking Statements

Forward-Looking Statements The disclosure under this Item 8.01 contains "forward-looking statements" of Adicet within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the business and operations of Adicet. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding Adicet's expectations for its Phase 1 trial of ADI-001 in autoimmune diseases, including plans to initiate enrollment of patients with SLE, SSc and AAV in the fourth quarter of this year and to report preliminary clinical data in LN, SLE, SSc and AAV in the first half of 2025. Any forward-looking statements in this Item 8.01 are based on management's current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including without limitation, the effect of global economic conditions and public health crises on the Company's business and financial results, including with respect to disruptions to its preclinical and clinical studies, business operations, employee hiring and retention, and ability to raise additional capital; Adicet's ability to execute on its strategy including obtaining the requisite regulatory approvals on the expected timeline, if at all; that positive results, including interim results, from a preclinical or clinical study may not necessarily be predictive of the results of future or ongoing studies; that clinical studies may fail to demonstrate adequate safety and efficacy of Adicet's product candidates, which woul

01 Exhibits

Item 9.01 Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by Adicet Bio, Inc. on September 30, 2024, furnished herewith. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ADICET BIO, INC. Date: September 30, 2024 By: /s/ Nick Harvey Name: Title: Nick Harvey Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR